BioSpaceOriginal article
As AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune vision
Phase 2positiveSkyriziPositive
AI Analysis
Summary
AbbVie's next-generation dual-targeting therapy produced higher remission rates than Skyrizi in a Phase 2a Crohn's disease trial. Analysts praised AbbVie's autoimmune strategy and questioned whether the blockbuster Skyrizi can be outdone.
Clinical Trial Data
Phase
Phase 2a
Outcome Details
AbbVie's next-gen dual-targeting combination therapy elicited higher remission rates than Skyrizi (IL-23 inhibitor) in a Phase 2a trial in Crohn's disease.
Importance:7/10
Sentiment:
0.60
Crohn's diseaseautoimmunePhase 2combination therapyIL-23dual-targetinghead-to-head
Read the original article
Published by BioSpace on October 19, 2026 3:02 PM